March 14, 2025 03:23 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
In a setback for Donald Trump, US judge orders federal agencies to rehire fired workers: Report | 'We will thwart conspiracies hatched by Centre': Revanth Reddy on delimitation exercise | Chennai doctor, his wife along with two sons die by suicide due to huge debt: Cops | Amid language debate, Tamil Nadu drops rupee symbol in state budget | Scientist killed in assault by neighbour over parking argument in Mohali | British woman tourist raped in Delhi hotel by man she befriended on social media | Gold smuggling case: Court restrains media from publishing, telecasting defamatory statements against Ranya Rao | Trump warns Putin of 'devastating' financial impacts if Russia blocks Ukraine ceasefire | 'People are going to Russia right now as we speak: Donald Trump on Ukraine war ceasefire talks | Pakistani army claims to have freed all hostages in passenger train siege; 28 personnel killed
AstraZeneca
Image Credit: Wikimedia Commons

US phase 3 trial data shows 79% vaccine efficacy against symptomatic COVID-19: AstraZeneca

| @indiablooms | Mar 23, 2021, at 03:39 am

Ontario/IBNS: Advanced trial data from a US study on AstraZeneca coronavirus vaccine showed it is 79 per cent effective at preventing symptomatic COVID-19 and was 100 per cent effective in halting severe disease and hospitalization, said AstraZeneca in a statement on Monday.

It was reported by the investigators that the vaccine was effective across adults of all ages, including older people, which other countries with previous studies had failed to establish.

"These findings reconfirm previous results observed," said Ann Falsey of the University of Rochester School of Medicine, who helped lead the trial. "It's exciting to see similar efficacy results in people over 65 for the first time," CBC News reported. 

Also, no safety concerns related to the vaccine were identified by AstraZeneca's experts, including a rare blood clot that was identified in Europe.

It was found by the scientists that there was no increased risk of clots among the more than 20,000 people who got at least one dose of the shot, which was developed with Oxford University. 

"Vaccine efficacy was consistent across ethnicity and age. Notably, in participants aged 65 years and over, vaccine efficacy was 80%. Amongst participants in the interim analysis, approximately 79% were white/Caucasian, 8% black/African American, 4% native American and 4% Asian, and 22% of participants were Hispanic," the pharmaceutical company said in a statement.

Although the vaccine has been approved for use in 50 countries, including Canada, it has not yet been approved in the US.

Canada is expected to receive 1.5 million doses of the AstraZeneca-Oxford product from the U.S. government this week.
 

(Reporting by Asha Bajaj)

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.